Methods and compositions for therapeutic agents
The present disclosure provides inter alia compositions that comprise therapeutic agents (e.g., live attenuated viral antigens, therapeutic proteins, etc.) and a lipid component. The lipid component may comprise or consist of different types of lipid or lipids as described herein. In some embodiments the therapeutic agents are thermolabile. The present disclosure also provides methods for preparing compositions, including the aforementioned compositions (e.g., melt methods and spray injection methods among others).
1. A method comprising:
preparing pre-formed vesicles comprising a lipid component that comprises a non-ionic surfactant, a steroid and an ionic amphiphile;
admixing the pre-formed vesicles with an aqueous solution that includes a thermolabile therapeutic agent, wherein pre-formed vesicles are prepared in the absence of thermolabile therapeutic agent;
homogenizing the resulting product to form a homogenate, wherein the homogenate does not comprise thermolabile therapeutic agent entrapped within the pre-formed vesicles; and
lyophilizing the homogenate to form a lyophilized homogenate,
wherein the ionic amphiphile is dicetylphosphate (DCP) or 1,2-dipalmitoylphosphatidyl glycerol (DPPG), and
when the ionic amphiphile is DCP, the non-ionic surfactant is 1-monopalmitoyl glycerol (MPG) and the steroid is cholesterol (CHO); and
when the ionic amphiphile is DPPG, the non-ionic surfactant is MPG and the steroid is CHO and the MPG, CHO, and DPPG are present in a ratio of 5:4:1.
2. The method of claim 1 , wherein the ionic amphiphile is DCP.
3. The method of claim 1 , wherein the ionic amphiphile is DPPG.
4. The method of claim 1 , wherein preparing the pre-formed vesicles comprises:
(a) melting the lipid component, and adding the molten lipid component to an aqueous solution that lacks the thermolabile therapeutic agent; or
(b) melting the lipid component, and adding an aqueous solution that lacks the thermolabile therapeutic agent to molten lipid component.
5. The method of claim 1 , wherein the thermolabile therapeutic agent comprises:
(a) an attenuated measles virus, an attenuated mumps virus, an attenuated rubella virus, and attenuated varicella virus, or a combination thereof;
(b) an attenuated virus selected from the group consisting of an attenuated rotavirus, an attenuated herpes zoster virus, an attenuated vaccinia virus, an attenuated yellow fever virus, and combinations thereof;
(c) a therapeutic protein; or
(d) a polynucleotide or polysaccharide.
6. The method of claim 1 , wherein the lyophilized homogenate possesses higher stability at temperatures greater than 4 degrees Celsius when compared to a lyophilized immunogenic composition consisting of the thermolabile therapeutic agent.
7. The method of claim 5 , wherein the therapeutic protein is an antibody.
8. The method of claim 5 , wherein the therapeutic protein is an antibody fragment.